Get the app!
Back to Trades
Other3

Evommune, Inc.

EVMN

Total Value
$NaN

Company Information

Company Name
Evommune, Inc.
Ticker Symbol
EVMN
CIK
0002044725

Insider Information

Role
Insider
Location
BOSTON, MA

Filing Details

Filing Date
Nov 5, 2025
Transaction Date
Nov 5, 2025
Accession Number
0001231919-25-000435
Form Type
3

Footnotes

  1. (F1)The Series C Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock will be converted into shares of Common Stock of the Issuer.
  2. (F2)RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  3. (F3)Held directly by the Fund.
  4. (F4)Held directly by the Nexus Fund III.

SEC Filing

View on SEC Daily

View the complete filing document on SEC Daily.